Search

Your search keyword '"Lockhart, Albert C."' showing total 145 results
Start Over Author "Lockhart, Albert C."
145 results on '"Lockhart, Albert C."'

1. Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Published
2022
Full Text
View/download PDF

3. Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study

Author

Wang-Gillam, Andrea, primary, Lim, Kian-Huat, additional, McWilliams, Robert, additional, Suresh, Rama, additional, Lockhart, Albert C., additional, Brown, Amberly, additional, Breden, Marcus, additional, Belle, Jad I., additional, Herndon, John, additional, Bogner, Savannah J., additional, Pedersen, Katrina, additional, Tan, Benjamin, additional, Boice, Nicholas, additional, Acharya, Abhi, additional, Abdiannia, Mina, additional, Gao, Feng, additional, Yoon, Harry H., additional, Zhu, Mojun, additional, Trikalinos, Nikolaos A., additional, Ratner, Lee, additional, Aranha, Olivia, additional, Hawkins, William G., additional, Herzog, Brett H., additional, and DeNardo, David G., additional

Published
2023
Full Text
View/download PDF

4. Table S1 from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Author

Wang-Gillam, Andrea, primary, Lim, Kian-Huat, primary, McWilliams, Robert, primary, Suresh, Rama, primary, Lockhart, Albert C., primary, Brown, Amberly, primary, Breden, Marcus, primary, Belle, Jad I., primary, Herndon, John, primary, Bogner, Savannah J., primary, Pedersen, Katrina, primary, Tan, Benjamin, primary, Boice, Nicholas, primary, Acharya, Abhi, primary, Abdiannia, Mina, primary, Gao, Feng, primary, Yoon, Harry H., primary, Zhu, Mojun, primary, Trikalinos, Nikolaos A., primary, Ratner, Lee, primary, Aranha, Olivia, primary, Hawkins, William G., primary, Herzog, Brett H., primary, and DeNardo, David G., primary

Published
2023
Full Text
View/download PDF

5. Data from Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Author

Wang-Gillam, Andrea, primary, Lim, Kian-Huat, primary, McWilliams, Robert, primary, Suresh, Rama, primary, Lockhart, Albert C., primary, Brown, Amberly, primary, Breden, Marcus, primary, Belle, Jad I., primary, Herndon, John, primary, Bogner, Savannah J., primary, Pedersen, Katrina, primary, Tan, Benjamin, primary, Boice, Nicholas, primary, Acharya, Abhi, primary, Abdiannia, Mina, primary, Gao, Feng, primary, Yoon, Harry H., primary, Zhu, Mojun, primary, Trikalinos, Nikolaos A., primary, Ratner, Lee, primary, Aranha, Olivia, primary, Hawkins, William G., primary, Herzog, Brett H., primary, and DeNardo, David G., primary

Published
2023
Full Text
View/download PDF

6. The soluble guanylyl cyclase pathway is inhibited to evade androgen deprivation-induced senescence and enable progression to castration resistance

Author

Rai, Priyamvada, primary, Zhang, Ling, additional, Troccoli, Clara I., additional, Mateo-Victoriano, Beatriz, additional, Misiara, Laura, additional, Jackson, Erin N, additional, Shu, Ping, additional, Plastini, Trisha M, additional, Tao, Wensi, additional, Kwon, Deukwoo, additional, Chen, Xi, additional, Sharma, Janaki, additional, Jorda, Merce, additional, Gulley, James L, additional, Bilusic, Marijo, additional, Lockhart, Albert C, additional, and Beuve, Annie, additional

Published
2023
Full Text
View/download PDF

7. Long non-coding RNA RAMS11 promotes metastatic colorectal cancer progression

Author

Silva-Fisher, Jessica M., Dang, Ha X., White, Nicole M., Strand, Matthew S., Krasnick, Bradley A., Rozycki, Emily B., Jeffers, Gejae G. L., Grossman, Julie G., Highkin, Maureen K., Tang, Cynthia, Cabanski, Christopher R., Eteleeb, Abdallah, Mudd, Jacqueline, Goedegebuure, S. Peter, Luo, Jingqin, Mardis, Elaine R., Wilson, Richard K., Ley, Timothy J., Lockhart, Albert C., Fields, Ryan C., and Maher, Christopher A.

Published
2020
Full Text
View/download PDF

8. Figure S5 from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

Author

Arai, Hiroyuki, primary, Elliott, Andrew, primary, Xiu, Joanne, primary, Wang, Jingyuan, primary, Battaglin, Francesca, primary, Kawanishi, Natsuko, primary, Soni, Shivani, primary, Zhang, Wu, primary, Millstein, Joshua, primary, Sohal, Davendra, primary, Goldberg, Richard M., primary, Hall, Michael J., primary, Scott, Aaron J., primary, Khushman, Moh'd, primary, Hwang, Jimmy J., primary, Lou, Emil, primary, Weinberg, Benjamin A., primary, Marshall, John L., primary, Lockhart, Albert C., primary, Stafford, Phillip, primary, Zhang, Jian, primary, Moretto, Roberto, primary, Cremolini, Chiara, primary, Korn, W. Michael, primary, and Lenz, Heinz-Josef, primary

Published
2023
Full Text
View/download PDF

9. Supplementary Methods from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

Author

Arai, Hiroyuki, primary, Elliott, Andrew, primary, Xiu, Joanne, primary, Wang, Jingyuan, primary, Battaglin, Francesca, primary, Kawanishi, Natsuko, primary, Soni, Shivani, primary, Zhang, Wu, primary, Millstein, Joshua, primary, Sohal, Davendra, primary, Goldberg, Richard M., primary, Hall, Michael J., primary, Scott, Aaron J., primary, Khushman, Moh'd, primary, Hwang, Jimmy J., primary, Lou, Emil, primary, Weinberg, Benjamin A., primary, Marshall, John L., primary, Lockhart, Albert C., primary, Stafford, Phillip, primary, Zhang, Jian, primary, Moretto, Roberto, primary, Cremolini, Chiara, primary, Korn, W. Michael, primary, and Lenz, Heinz-Josef, primary

Published
2023
Full Text
View/download PDF

10. Phosphorylation of IRAK4 is present in early-passage patient-derived cell lines and independent pancreatic tissue microarray from Constitutive IRAK4 Activation Underlies Poor Prognosis and Chemoresistance in Pancreatic Ductal Adenocarcinoma

Author

Zhang, Daoxiang, primary, Li, Lin, primary, Jiang, Hongmei, primary, Knolhoff, Brett L., primary, Lockhart, Albert C., primary, Wang-Gillam, Andrea, primary, DeNardo, David G., primary, Ruzinova, Marianna B., primary, and Lim, Kian-Huat, primary

Published
2023
Full Text
View/download PDF

11. Supplementary Tables from The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

Author

Arai, Hiroyuki, primary, Elliott, Andrew, primary, Xiu, Joanne, primary, Wang, Jingyuan, primary, Battaglin, Francesca, primary, Kawanishi, Natsuko, primary, Soni, Shivani, primary, Zhang, Wu, primary, Millstein, Joshua, primary, Sohal, Davendra, primary, Goldberg, Richard M., primary, Hall, Michael J., primary, Scott, Aaron J., primary, Khushman, Moh'd, primary, Hwang, Jimmy J., primary, Lou, Emil, primary, Weinberg, Benjamin A., primary, Marshall, John L., primary, Lockhart, Albert C., primary, Stafford, Phillip, primary, Zhang, Jian, primary, Moretto, Roberto, primary, Cremolini, Chiara, primary, Korn, W. Michael, primary, and Lenz, Heinz-Josef, primary

Published
2023
Full Text
View/download PDF

12. Supplementary Data from First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Author

Papadopoulos, Kyriakos P., primary, Johnson, Melissa L., primary, Lockhart, Albert C., primary, Moore, Kathleen, primary, Falchook, Gerald S., primary, Formenti, Silvia C., primary, Naing, Aung, primary, Carvajal, Richard D., primary, Rosen, Lee S., primary, Weiss, Glen J., primary, Leidner, Rom S., primary, Li, Jingjin, primary, Paccaly, Anne, primary, Feng, Minjie, primary, Stankevich, Elizabeth, primary, Lowy, Israel, primary, Fury, Matthew G., primary, and Crittenden, Marka R., primary

Published
2023
Full Text
View/download PDF

15. Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Author

Wang-Gillam, Andrea, primary, Lim, Kian-Huat, additional, McWilliams, Robert, additional, Suresh, Rama, additional, Lockhart, Albert C., additional, Brown, Amberly, additional, Breden, Marcus, additional, Belle, Jad I., additional, Herndon, John, additional, Bogner, Savannah J., additional, Pedersen, Katrina, additional, Tan, Benjamin, additional, Boice, Nicholas, additional, Acharya, Abhi, additional, Abdiannia, Mina, additional, Gao, Feng, additional, Yoon, Harry H., additional, Zhu, Mojun, additional, Trikalinos, Nikolaos A., additional, Ratner, Lee, additional, Aranha, Olivia, additional, Hawkins, William G., additional, Herzog, Brett H., additional, and DeNardo, David G., additional

Published
2022
Full Text
View/download PDF

16. Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Author

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler, Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, José, and Solit, David B.

Published
2019
Full Text
View/download PDF

17. Additional file 2 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Subjects
Data_FILES
Abstract

Additional file 2.

Published
2022
Full Text
View/download PDF

18. Additional file 1 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Subjects
Data_FILES
Abstract

Additional file 1.

Published
2022
Full Text
View/download PDF

19. Additional file 3 of Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction

Author

Voon, Pei Jye, Chen, Eric X., Chen, Helen X., Lockhart, Albert C., Sahebjam, Solmaz, Kelly, Karen, Vaishampayan, Ulka N., Subbiah, Vivek, Razak, Albiruni R., Renouf, Daniel J., Hotte, Sebastien J., Singh, Arti, Bedard, Philippe L., Hansen, Aaron R., Ivy, S. Percy, Wang, Lisa, Stayner, Lee-Anne, Siu, Lillian L., and Spreafico, Anna

Subjects
Data_FILES
Abstract

Additional file 3.

Published
2022
Full Text
View/download PDF

20. Abstract P035: A phase 1 pharmacokinetic trial of single agent trametinib a MEK inhibitor in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study (NCI 9591)

Author

Voon, Pei Jye, primary, Chen, Eric X., additional, Chen, Helen X., additional, Lockhart, Albert C., additional, Sahebjam, Solmaz, additional, Kelly, Karen, additional, Vaishampayan, Ulka N., additional, Subbiah, Vivek, additional, Razak, Albiruni R., additional, Renouf, Daniel J., additional, Hotte, Sebastien J., additional, Singh, Arti, additional, Bedard, Philippe L., additional, Hansen, Aaron R., additional, Percy, Ivy S., additional, Wang, Lisa, additional, Stayner, Lee-Anne, additional, Siu, Lillian L., additional, and Spreafico, Anna, additional

Published
2021
Full Text
View/download PDF

21. Phase I Pharmacokinetic Study of Single Agent Trametinib in Patients With Advanced Cancer and Hepatic Dysfunction

Author

Voon, Pei Jye, primary, Chen, Eric X., additional, Chen, Helen X., additional, Lockhart, Albert C., additional, Sahebjam, Solmaz, additional, Kelly, Karen, additional, Vaishampayan, Ulka N., additional, Subbiah, Vivek, additional, Razak, Albiruni R., additional, Renouf, Daniel J., additional, Hotte, Sebastien J., additional, Singh, Arti, additional, Bedard, Philippe L., additional, Hansen, Aaron R., additional, Ivy, S. Percy, additional, Wang, Lisa, additional, Stayner, Lee-Anne, additional, Siu, Lillian L., additional, and Spreafico, Anna, additional

Published
2021
Full Text
View/download PDF

22. HER kinase inhibition in patients with HER2- and HER3-mutant cancers

Author

Hyman, David M., Piha-Paul, Sarina A., Won, Helen, Rodon, Jordi, Saura, Cristina, Shapiro, Geoffrey I., Juric, Dejan, Quinn, David I., Moreno, Victor, Doger, Bernard, Mayer, Ingrid A., Boni, Valentina, Calvo, Emiliano, Loi, Sherene, Lockhart, Albert C., Erinjeri, Joseph P., Scaltriti, Maurizio, Ulaner, Gary A., Patel, Juber, Tang, Jiabin, Beer, Hannah, Selcuklu, S. Duygu, Hanrahan, Aphrothiti J., Bouvier, Nancy, Melcer, Myra, Murali, Rajmohan, Schram, Alison M., Smyth, Lillian M., Jhaveri, Komal, Li, Bob T., Drilon, Alexander, Harding, James J., Iyer, Gopa, Taylor, Barry S., Berger, Michael F., Cutler Jr, Richard E., Xu, Feng, Butturini, Anna, Eli, Lisa D., Mann, Grace, Farrell, Cynthia, Lalani, Alshad S., Bryce, Richard P., Arteaga, Carlos L., Meric-Bernstam, Funda, Baselga, Jos, and Solit, David B.

Subjects
Cancer -- Genetic aspects, Phosphotransferases -- Health aspects, Gene mutation -- Health aspects, Environmental issues, Science and technology, Zoology and wildlife conservation
Abstract

Somatic mutations of ERBB2 and ERBB3 (which encode HER2 and HER3, respectively) are found in a wide range of cancers. Preclinical modelling suggests that a subset of these mutations lead to constitutive HER2 activation, but most remain biologically uncharacterized. Here we define the biological and therapeutic importance of known oncogenic HER2 and HER3 mutations and variants of unknown biological importance by conducting a multi-histology, genomically selected, basket trial using the pan-HER kinase inhibitor neratinib (SUMMIT; clinicaltrials.gov identifier NCT01953926). Efficacy in HER2-mutant cancers varied as a function of both tumour type and mutant allele to a degree not predicted by preclinical models, with the greatest activity seen in breast, cervical and biliary cancers and with tumours that contain kinase domain missense mutations. This study demonstrates how a molecularly driven clinical trial can be used to refine our biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology., Author(s): David M. Hyman (corresponding author) [1]; Sarina A. Piha-Paul [2]; Helen Won [1]; Jordi Rodon [3]; Cristina Saura [3]; Geoffrey I. Shapiro [4]; Dejan Juric [5]; David I. Quinn [...]

Published
2018
Full Text
View/download PDF

24. The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer

Author

Arai, Hiroyuki, primary, Elliott, Andrew, additional, Xiu, Joanne, additional, Wang, Jingyuan, additional, Battaglin, Francesca, additional, Kawanishi, Natsuko, additional, Soni, Shivani, additional, Zhang, Wu, additional, Millstein, Joshua, additional, Sohal, Davendra, additional, Goldberg, Richard M., additional, Hall, Michael J., additional, Scott, Aaron J., additional, Khushman, Moh'd, additional, Hwang, Jimmy J., additional, Lou, Emil, additional, Weinberg, Benjamin A., additional, Marshall, John L., additional, Lockhart, Albert C., additional, Stafford, Phillip, additional, Zhang, Jian, additional, Moretto, Roberto, additional, Cremolini, Chiara, additional, Korn, W. Michael, additional, and Lenz, Heinz-Josef, additional

Published
2021
Full Text
View/download PDF

25. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies

Author

Papadopoulos, Kyriakos P., primary, Johnson, Melissa L., additional, Lockhart, Albert C., additional, Moore, Kathleen, additional, Falchook, Gerald S., additional, Formenti, Silvia C., additional, Naing, Aung, additional, Carvajal, Richard D., additional, Rosen, Lee S., additional, Weiss, Glen J., additional, Leidner, Rom S., additional, Li, Jingjin, additional, Paccaly, Anne, additional, Feng, Minjie, additional, Stankevich, Elizabeth, additional, Lowy, Israel, additional, Fury, Matthew G., additional, and Crittenden, Marka R., additional

Published
2020
Full Text
View/download PDF

27. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer

Author

Amin, Manik, primary, Desai, Monica, additional, Trinkaus, Kathryn, additional, Brown, Amberly, additional, Wang-Gillam, Andrea, additional, Tan, Benjamin, additional, Picus, Joel, additional, Sorscher, Steven, additional, Highkin, Maureen, additional, Lears, Kim, additional, and Lockhart, Albert C., additional

Published
2019
Full Text
View/download PDF

28. Phase Ib Results of the Rational Combination of Selumetinib and Cyclosporin A in Advanced Solid Tumors with an Expansion Cohort in Metastatic Colorectal Cancer

Author

Krishnamurthy, Anuradha, primary, Dasari, Arvind, additional, Noonan, Anne M., additional, Mehnert, Janice M., additional, Lockhart, Albert C., additional, Leong, Stephen, additional, Capasso, Anna, additional, Stein, Mark N., additional, Sanoff, Hanna K., additional, Lee, James J., additional, Hansen, Aaron, additional, Malhotra, Usha, additional, Rippke, Sarah, additional, Gustafson, Daniel L., additional, Pitts, Todd M., additional, Ellison, Kim, additional, Davis, S. Lindsey, additional, Messersmith, Wells A., additional, Eckhardt, S. Gail, additional, and Lieu, Christopher H., additional

Published
2018
Full Text
View/download PDF

29. Abstract CT001: Neratinib in HER2 or HER3 mutant solid tumors: SUMMIT, a global, multi-histology, open-label, phase 2 "basket" study

Author

Hyman, David M., primary, Piha-Paul, Sarina A., additional, Rodon, Jordi, additional, Saura, Cristina, additional, Shapiro, Geoffrey I., additional, Quinn, David I., additional, Moreno, Victor, additional, Mayer, Ingrid A., additional, Arteaga, Carlos, additional, Boni, Valentina, additional, Calvo, Emiliano, additional, Loi, Sherene, additional, Lockhart, Albert C., additional, Smyth, Lillian M., additional, Erinjeri, Joseph, additional, Scaltriti, Maurizio, additional, Ulaner, Gary, additional, Torrisi, Jean, additional, Patel, Juber, additional, Tang, Jiabin, additional, Meng, Fanli, additional, Selcuklu, Duygu, additional, Won, Helen, additional, Bouvier, Nancy, additional, Berger, Michael F., additional, Cutler, Richard E., additional, Xu, Feng, additional, Butturini, Anna, additional, Eli, Lisa D., additional, Mann, Grace, additional, Lalani, Alshad S., additional, Bryce, Richard P., additional, Meric-Bernstam, Funda, additional, Baselga, José, additional, and Solit, David B., additional

Published
2017
Full Text
View/download PDF

30. CheckMate 577: A randomized, double-blind, phase 3 study of adjuvant nivolumab (nivo) or placebo in pts with resected esophageal (E) or gastroesophageal junction (GEJ) cancer.

Author

Kelly, Ronan Joseph, primary, Lockhart, Albert C., additional, Jonker, Derek J., additional, Melichar, Bohuslav, additional, Andre, Thierry, additional, Chau, Ian, additional, Clarke, Stephen John, additional, Cleary, James M., additional, Doki, Yuichiro, additional, Franke, Fabio A., additional, Kitagawa, Yuko, additional, Mariette, Christophe, additional, Montenegro, Paola Catherine, additional, Mendez, Guillermo Ariel, additional, Ciprotti, Marika, additional, and Moehler, Markus H., additional

Published
2017
Full Text
View/download PDF

31. Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.

Author

Doi, Toshihiko, primary, Iwata, Hiroji, additional, Tsurutani, Junji, additional, Takahashi, Shunji, additional, Park, Haeseong, additional, Redfern, Charles H., additional, Shitara, Kohei, additional, Shimizu, Chikako, additional, Taniguchi, Hiroya, additional, Iwasa, Tsutomu, additional, Taira, Shinichiro, additional, Lockhart, Albert C., additional, Fisher, Jennifer M., additional, Jikoh, Takahiro, additional, Fujisaki, Yoshihiko, additional, Lee, Caleb C., additional, Yver, Antoine, additional, and Tamura, Kenji, additional

Published
2017
Full Text
View/download PDF

32. Phase I study combining MLN8237 with nab-paclitaxel in patients with advanced solid malignancies.

Author

Lim, Kian-Huat, primary, Lockhart, Albert C., additional, Waqar, Saiama Naheed, additional, Govindan, Ramaswamy, additional, Morgensztern, Daniel, additional, Picus, Joel, additional, Tan, Benjamin R., additional, Baggstrom, Maria Quintos, additional, Ratchford, Emily, additional, Marquez, Samantha, additional, and Wang-Gillam, Andrea, additional

Published
2017
Full Text
View/download PDF

34. A phase IB study of the combination of selumetinib (AZD6244; ARRY-142886) and cyclosporin A (CsA) in patients with advanced solid tumors with an expansion cohort in metastatic colorectal cancer (mCRC).

Author

Krishnamurthy, Anuradha, primary, Dasari, A., additional, Lockhart, Albert C., additional, Stein, Mark N., additional, Sanoff, Hanna Kelly, additional, Lee, James J., additional, Hansen, Aaron Richard, additional, Bekaii-Saab, Tanios S., additional, Malhotra, Usha, additional, Rippke, Sarah, additional, Davis, Sarah Lindsey, additional, Messersmith, Wells A., additional, Yao, James C., additional, Meric-Bernstam, Funda, additional, Eckhardt, S. Gail, additional, and Lieu, Christopher Hanyoung, additional

Published
2017
Full Text
View/download PDF

35. A National Cancer Database analysis of treatment utilization and associated outcomes in elderly patients with locally advanced esophageal cancer.

Author

Vlacich, Gregory Riccardo, primary, Samson, Pamela Parker, additional, Perkins, Stephanie Mabry, additional, Roach, Michael Charles, additional, Parikh, Parag J., additional, Bradley, Jeffrey D., additional, Lockhart, Albert C., additional, Puri, Varun, additional, Meyers, Bryan F, additional, Kozower, Benjamin D., additional, and Robinson, Cliff Grant, additional

Published
2017
Full Text
View/download PDF

37. A phase 1b/2, open label, dose-escalation study of margetuximab (M) in combination with pembrolizumab (P) in patients with relapsed/refractory advanced HER2+ gastroesophageal (GEJ) junction or gastric (G) cancer.

Author

Catenacci, Daniel V.T., primary, Kim, Sunnie S., additional, Gold, Philip Jordan, additional, Philip, Philip Agop, additional, Enzinger, Peter C., additional, Coffie, Joe, additional, Schmidt, Emmett V., additional, Baldwin, Malcolm, additional, Nordstrom, Jeffrey L., additional, Bonvini, Ezio, additional, Wigginton, Jon M., additional, Hochster, Howard S., additional, Denlinger, Crystal Shereen, additional, Uronis, Hope Elizabeth, additional, Bendell, Johanna C., additional, Kelly, Ronan Joseph, additional, Davidson-Moncada, Jan Kenneth, additional, and Lockhart, Albert C., additional

Published
2017
Full Text
View/download PDF

38. CheckMate 577: A randomized, double-blind, phase 3 study of nivolumab (Nivo) or placebo in patients (Pts) with resected lower esophageal (E) or gastroesophageal junction (GEJ) cancer.

Author

Kelly, Ronan Joseph, primary, Lockhart, Albert C., additional, Jonker, Derek J., additional, Melichar, Bohuslav, additional, Andre, Thierry, additional, Chau, Ian, additional, Clarke, Stephen John, additional, Cleary, James M., additional, Doki, Yuichiro, additional, Franke, Fabio Andre, additional, Kitagawa, Yuko, additional, Mariette, Christophe, additional, Montenegro, Paola Catherine, additional, Roca, Enrique Luis, additional, Ciprotti, Marika, additional, and Moehler, Markus, additional

Published
2017
Full Text
View/download PDF

40. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

Author

Hyman, David Michael, Jaime, Jesus Corral, Garralda, Elena, Machiels, Jean-Pascal H., Schellens, Jan H. M., Bedard, Phillipe, Campone, Mario, Cassier, Philippe, Sarantopoulos, John, Vaishampayan, Ulka N., Chugh, Rashmi, Mahipal, Amit, Lockhart, Albert C., Sessa, Cristiana, Zander, Thomas, Ng, Matthew, Curigliano, Giuseppe, Bendiske, Jennifer, Perez-Garcia, Jose Manuel, Hyman, David Michael, Jaime, Jesus Corral, Garralda, Elena, Machiels, Jean-Pascal H., Schellens, Jan H. M., Bedard, Phillipe, Campone, Mario, Cassier, Philippe, Sarantopoulos, John, Vaishampayan, Ulka N., Chugh, Rashmi, Mahipal, Amit, Lockhart, Albert C., Sessa, Cristiana, Zander, Thomas, Ng, Matthew, Curigliano, Giuseppe, Bendiske, Jennifer, and Perez-Garcia, Jose Manuel

Published
2016

42. Neoadjuvant chemotherapy versus chemoradiation prior to esophagectomy: Impact on rate of complete pathologic response and survival in esophageal cancer patients.

Author

Lockhart, Albert C., primary, Samson, Pamela Parker, additional, Robinson, Cliff Grant, additional, Bradley, Jeffrey D., additional, Puri, Varun, additional, Broderick, Stephen R., additional, Patterson, G Alexander, additional, Meyers, Bryan F, additional, and Crabtree, Traves, additional

Published
2016
Full Text
View/download PDF

43. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity.

Author

Disis, Mary L., primary, Patel, Manish R., additional, Pant, Shubham, additional, Hamilton, Erika Paige, additional, Lockhart, Albert C., additional, Kelly, Karen, additional, Beck, J. Thaddeus, additional, Gordon, Michael S., additional, Weiss, Glen J., additional, Taylor, Matthew H., additional, Chaves, Jorge, additional, Mita, Alain C., additional, Chin, Kevin M., additional, von Heydebreck, Anja, additional, Cuillerot, Jean-Marie, additional, and Gulley, James L., additional

Published
2016
Full Text
View/download PDF

45. A first-in-human study of REGN2810, a monoclonal, fully human antibody to programmed death-1 (PD-1), in combination with immunomodulators including hypofractionated radiotherapy (hfRT).

Author

Papadopoulos, Kyriakos P., primary, Crittenden, Marka R., additional, Johnson, Melissa Lynne, additional, Lockhart, Albert C., additional, Moore, Kathleen N., additional, Falchook, Gerald Steven, additional, Formenti, Silvia, additional, Carvajal, Richard D., additional, Leidner, Rom S., additional, Naing, Aung, additional, Rosen, Lee S., additional, Weiss, Glen J., additional, Caldwell Iii, Wilson, additional, Gao, Bo, additional, Paccaly, Anne, additional, Stankevich, Elizabeth, additional, Trail, Pamela, additional, Fury, Matthew G., additional, and Lowy, Israel, additional

Published
2016
Full Text
View/download PDF

46. Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.

Author

Hyman, David Michael, primary, Tran, Ben, additional, Corral Jaime, Jesus, additional, Garralda, Elena, additional, Machiels, Jean-Pascal H., additional, Schellens, Jan H. M., additional, Bedard, Phillipe, additional, Campone, Mario, additional, Cassier, Philippe, additional, Sarantopoulos, John, additional, Vaishampayan, Ulka N., additional, Chugh, Rashmi, additional, Mahipal, Amit, additional, Lockhart, Albert C., additional, Sessa, Cristiana, additional, Zander, Thomas, additional, Ng, Matthew, additional, Curigliano, Giuseppe, additional, Bendiske, Jennifer, additional, and Perez-Garcia, Jose Manuel, additional

Published
2016
Full Text
View/download PDF

47. Investigational NEDD8-activating enzyme inhibitor pevonedistat (Pev) plus chemotherapy in patients (Pts) with solid tumors (Phase 1b study): Antitumor activity of pev plus carboplatin (Carbo)/paclitaxel (Pac).

Author

Bauer, Todd Michael, primary, Harvey, R Donald, additional, Lee, Carrie B., additional, Aggarwal, Charu, additional, Cohen, Roger B., additional, Sedarati, Farhad, additional, Teng, Zhaoyang, additional, Faessel, Hélène M., additional, Dash, Ajeeta, additional, Dezube, Bruce J., additional, Santillana, Sergio, additional, Dowlati, Afshin, additional, and Lockhart, Albert C., additional

Published
2016
Full Text
View/download PDF

48. Phase I pharmacokinetic study of single agent trametinib in advanced cancer patients with hepatic dysfunction: An NCI Organ Dysfunction Working Group (ODWG) study.

Author

Spreafico, Anna, primary, Chen, Eric, additional, Sahebjam, Solmaz, additional, Renouf, Daniel John, additional, Kelly, Karen, additional, Lockhart, Albert C., additional, Vaishampayan, Ulka N., additional, Hotte, Sebastien J., additional, Razak, Albiruni R., additional, Wang, Lisa, additional, Stayner, Lee-Anne, additional, Bougie, Alanna, additional, Chen, Helen X., additional, Ivy, S. Percy, additional, and Siu, Lillian L., additional

Published
2016
Full Text
View/download PDF

49. A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors.

Author

Patel, Manish R., primary, Fakih, Marwan, additional, Olszanski, Anthony J., additional, Lockhart, Albert C., additional, Drilon, Alexander E., additional, Fu, Siqing, additional, Bazhenova, Lyudmila, additional, Patel, Rupal, additional, Oliver, Jennifer W., additional, Multani, Pratik S., additional, and Wang, Ding, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results